After a Type C discussion, Blue Lake got the FDA nod to enrol both RSV-positive and negative children above the age of 18 ...

Veterans aged 60 years and older who received a single dose of the respiratory syncytial virus (RSV) prefusion F3 (RSVPreF3) or RSV prefusion F (RSVpreF) vaccine remained protecte ...

The RSV shot isn't suggested for everyone like the flu vaccine is. Here's who is at risk and how to get a shot.

According to county data, only around 7% of residents have received COVID-19 boosters this season, and 22% have gotten flu ...

Some hospitals are reporting an uptick in respiratory syncytial virus hospitalizations in recent days, though national data — delayed by the federal shutdown — has yet to offer a clear picture.

A pooled multicountry analysis shows that immunisation with nirsevimab effectively reduced RSV-related hospitalisation in ...

The preventive effects of nirsevimab against respiratory syncytial virus infection persisted for up to 12 months after ...

The CDC monitors respiratory illness activity by looking at a range of diagnoses from emergency department (ED) visits, ...

VBY329 is designed for the prevention of Respiratory Syncytial Virus (RSV) infections in newborns, infants, and children, and results from ...

Two new studies suggest that nirsevimab (Beyfortus) is 80% to 89% effective in protecting infants from poor respiratory syncytial virus (RSV) outcomes, and a third study ties a federal initiative to ...

Sanofi and AstraZeneca's Beyfortus (Nirsevimab) is now approved by the National Pharmaceutical Regulatory Agency (NPRA) and is available for the prevention of respiratory syncytial virus (RSV) lower ...

As the leaves begin to change and the temperature starts to cool, families are reminded of respiratory syncytial virus (RSV) ...